Revenue grew 31% year-over-year to EUR 200.1 million, with strong organic and acquisition-driven growth. Net profit rose 9%, and guidance for 2026 is maintained despite expected headwinds from Bilastine generics in Japan.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.